Oral rimegepant for migraine prevention
- 15 December 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 397 (10268), 4-5
- https://doi.org/10.1016/s0140-6736(20)32624-6
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in MiceAnnals of Neurology, 2020
- Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adultsCephalalgia, 2020
- Ubrogepant for the Treatment of MigraineThe New England Journal of Medicine, 2019
- Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteriesCephalalgia, 2019
- Targeting calcitonin gene-related peptide: a new era in migraine therapyThe Lancet, 2019
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trialThe Lancet, 2019
- Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adultsCephalalgia, 2018
- Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine preventionNeurology, 2014
- Randomized, controlled trial of telcagepant for the acute treatment of migraineNeurology, 2009
- Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of MigraineThe New England Journal of Medicine, 2004